Entropy Advances TRP-8803 to US Phase 2 in Depression
Filed with ASX · · 6 pages · English
Entropy Neurodynamics Limited on 6ix
In the deck
Earlier from Entropy Neurodynamics
- Application for quotation of securities - ENP
- Trading Halt
- TRP 8803 manufacturing secured for Phase 2/3 advancement
- Change of Director's Interest Notice - HJ
- Cleansing Notice
Later from Entropy Neurodynamics
- Appendix 4G and Corporate Governance Statement
- Investor Webinar Presentation
- Appendix 4E and 2026 Annual Report
- All Patients Improve, 50% Achieve 12-Week BED Remission
- Notification of Date of 2026 AGM
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics